ORR 42.5%: Roche Reports Promising Early-Phase Data of TIGIT Antibody Tiragolumab Combination Therapy in First-Line Unresectable Hepatocellular Carcinoma

According to the abstract information on the ASCO official website, Roche released early data on the first-line treatment with TIGIT monoclonal antibody tiragolumab in combination therapy for patients with unresectable locally advanced or metastatic hepatocellular carcinoma (uHCC). The Ib/II phase Morpheus-Liver study showed that, compared with the control group (atezolizumab + bevacizumab, n = 18), the tiragolumab + atezolizumab + bevacizumab combination therapy group (n = 40) achieved a higher objective response rate (ORR) and longer progression-free survival (PFS).

A total of 58 treatment-naive patients with uHCC were randomly assigned to receive either atezolizumab (1200mg IV) + bevacizumab (15mg/kg IV) every 3 weeks or tiragolumab (600mg IV) + atezolizumab + bevacizumab.

As of November 28, 2022, the median follow-up time for the tiragolumab combination therapy group was 14.0 months, compared to 11.8 months in the control group. The confirmed ORR in the tiragolumab combination therapy group was 42.5%, higher than 11.1% in the control group; the median PFS for the tiragolumab combination therapy group was 11.1 months (95% CI: 8.2-NE), while it was 4.2 months (95% CI: 1.6-7.4) in the control group, corresponding to a PFS hazard ratio (HR) of 0.42 (95% CI: 0.22-0.82). Similar ORR and PFS benefits were observed in the tiragolumab combination therapy group across both the PD-L1+ (n=23) and PD-L1- (n=27) subgroups.

In terms of safety, the probabilities of grade 3/4 treatment-related adverse reactions in the tiragolumab combination therapy group versus the control group were 27.5% vs 33.3%, and the probabilities of adverse reactions leading to any treatment discontinuation were 22.5% vs 22.2%.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

PharmaCube Reader Survey Questionnaire

Thank You for Your Support! We Look Forward to Your Feedback.

Scan the QR code to provide valuable suggestions